Phase I trial demonstrates tumor responses in advanced lung and pancreatic cancers, suggesting a promising new therapy.
An experimental PROTAC drug designed to degrade mutant KRASG12D produced tumor responses in patients with advanced non–small cell lung cancer and pancreatic ductal adenocarcinoma in a phase I trial, with limited toxicity. Investigators are now testing the therapy in combination regimens and later-stage studies as competition intensifies among companies developing drugs against the common cancer driver.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: